China ADR Privatizations: The Challenges of Getting the Best Deal
The stellar performance of China’s stock markets over the past twelve months (Shanghai +121%, Shenzhen +161%, and Hong Kong +17%) has led to a...
603 Views
Opening of E-commerce Channel to Change China's Drug Market
Numerous press outlets report that China’s Food & Drug Administration (CFDA) will release regulations permitting online sales of...
602 Views
Introducing Long Term Leaders - Focussed Insights for your Core Holdings
We are pleased to announce the roll out of our latest content vertical: Long Term Leaders. Under this category,  we have identified companies that...
497 Views
Smartkarma Originals
China Population Policies Impact on Healthcare Companies Series - Part 1
China's population problem is already very serious. So, the government has begun to take a series of measures to optimize fertility policies. We...
1.2k Views
Pre-IPO Beijing Mabworks Biotech - MIL62 Alone Cannot Save the Situation
This article mainly analyzed Mabworks Biotech in terms of the important clinical-stage drug candidates (MIL62, MIL93, MBS301, MIL97, MIL95, MIL86,...
492 Views